表紙:抗凝固拮抗薬の世界市場:薬剤タイプ別・流通経路別・地域別 - 規模、シェア、展望、機会分析(2021年~2028年)
市場調査レポート
商品コード
1027082

抗凝固拮抗薬の世界市場:薬剤タイプ別・流通経路別・地域別 - 規模、シェア、展望、機会分析(2021年~2028年)

Anticoagulant Reversal Drugs Market, by Drug Type, by Distribution Channel, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2021 - 2028

出版日: | 発行: Coherent Market Insights | ページ情報: 英文 160 Pages | 納期: 2-3営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=115.03円
抗凝固拮抗薬の世界市場:薬剤タイプ別・流通経路別・地域別 - 規模、シェア、展望、機会分析(2021年~2028年)
出版日: 2021年08月05日
発行: Coherent Market Insights
ページ情報: 英文 160 Pages
納期: 2-3営業日
  • 全表示
  • 概要
  • 目次
概要

世界の抗凝固拮抗薬市場規模は、抗凝固剤治療を必要とする虚血性脳卒中、肺塞栓症、深部静脈血栓症などの心疾患の増加により、活性化されると予想されます。

市場の参入企業による共同研究や買収活動の活発化は、世界の抗凝固拮抗薬市場を牽引すると予想されます。

当レポートでは、世界の抗凝固拮抗薬市場について調査しており、市場の展望、市場力学、動向分析、市場分析、競合情勢など、包括的な情報を提供しています。

目次

第1章 調査目的・前提条件

第2章 市場の展望

  • レポートの説明
    • 市場の定義および範囲
  • エグゼクティブサマリー
    • 市場内訳:薬剤タイプ別
    • 市場内訳:流通経路別
    • 市場内訳:地域別
  • コヒーレントオポチュニティマップ(COM)

第3章 市場力学、規制、動向分析

  • 市場力学
    • 促進要因
    • 抑制要因
    • 市場機会
  • 影響分析
  • パイプライン分析
  • PEST分析
  • 規制シナリオ
  • 市場動向
  • 主なハイライト
  • 償還シナリオ
  • 合併および買収

第4章 世界の抗凝固拮抗薬市場 - コロナウイルス(COVID-19)パンデミックの影響

  • 経済的影響
  • 臨床試験および医薬品開発への影響
  • 政府のイニシアチブ

第5章 世界の抗凝固拮抗薬市場:薬剤タイプ別(2017年~2028年)(百万米ドル)

  • イントロダクション
  • プロトロンビン複合体濃縮物
  • フィトナジオン
  • アンデキサネットアルファ
  • イダルシズマブ
  • プロタミン
  • その他

第6章 世界の抗凝固拮抗薬市場:流通経路別(2017年~2028年)(百万米ドル)

  • イントロダクション
  • 病院薬局
  • 小売薬局
  • その他

第7章 世界の抗凝固拮抗薬市場:地域別(2017年~2028年)(百万米ドル)

  • イントロダクション
  • 北米
  • ラテンアメリカ
  • 欧州
  • アジア太平洋
  • 中東
  • アフリカ

第8章 競合情勢

  • ヒートマップ分析
  • 市場シェア分析
    • Alexion Pharmaceuticals, Inc.
    • Boehringer Ingelheim GmbH
    • CSL Behring Limited
    • Pfizer Inc.
    • Octapharma AG
    • Bausch Health Companies Inc.
    • Amneal Pharmaceuticals Inc.
    • Fresenius Kabi AG
    • Perosphere Pharmaceuticals Inc.
    • Ferring Pharmaceuticals Inc.
    • Midas Pharma GmbH
    • Healthy Life Pharma Pvt. Ltd
    • Pharma Cure Laboratories
    • AMAG Pharmaceuticals, Inc.
    • SGPharma Pvt. Ltd.
    • Alps Pharmaceutical Ind. Co., Ltd.
    • Nischi Lifesciences
  • アナリストの見解

第9章 セクション

目次
Product Code: CMI4551

Anticoagulants are used for treating and preventing blood clots events. Phenprocoumon and warfarin are the most commonly used oral anticoagulant agents. Phenprocoumon and warfarin are categorized as vitamin K antagonists while rivaroxaban and dabigatran are categorized as non-vitamin K antagonist oral anticoagulants (NOACs). Vitamin K antagonists work by inhibiting the enzyme vitamin K epoxide reductase which leads to blockage of the hepatic synthesis of the active, reduced form of vitamin K. This reduced form of vitamin K is required for carboxylation of protein C, protein S, and coagulation factors II, VII, IX, and X. Non-vitamin K antagonist oral anticoagulants work in a selective manner by either inhibiting factor Xa (rivaroxaban, apixaban, edoxaban) or thrombin (dabigatran). Since, NOACs have a comparatively short half-life and fewer interactions, NOACs are easier to control and administer than warfarin and do not require regular monitoring to ensure their efficacy and safety. Anticoagulant reversal drugs work opposite to that of anticoagulation drugs by canceling out its anticoagulation effects and are needed to control life-threatening bleeding.

Market Dynamics

Increasing prevalence of cardiac events such as ischemic stroke, pulmonary embolism, deep vein thrombosis, and others which require anticoagulant therapy is expected to fuel the global anticoagulant reversal drugs market. For instance, according to an article published by the National Centers for Biotechnology Information in July 2020, there is an increasing prevalence of Ischemic heart disease across the globe, as it affects 1,655 per 100,000 individuals, which may rise up to 1,845 per 100,000 individuals by the year 2030. Furthermore, according to data provided by the American College of Cardiology Foundation, it was estimated that around 1.05 million people suffered from coronary diseases in the U.S. in 2019. Moreover, according to the Centers for Disease Control and prevention (CDC) report 2020, it is estimated that more than 800,000 people in the U.S. suffer from a heart attack every year.

Rising collaboration and acquisition activities by the market players is expected to drive the global anticoagulant reversal drugs market. For instance, in April 2016, Daiichi Sankyo Company, Limited announced a clinical collaboration agreement with Portola Pharmaceuticals, Inc. for the development of andexanet alfa in Japan as an anticoagulant reversal agent for Daiichi Sankyo's Factor Xa inhibitor, LIXIANA (edoxaban).

Key features of the study:

  • This report provides in-depth analysis of the global anticoagulant reversal drugs market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2021-2028), considering 2020 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global anticoagulant reversal drugs market based on the following parameters - company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
  • Key companies covered as a part of this study include Alexion Pharmaceuticals, Inc., Boehringer Ingelheim GmbH, CSL Behring Limited, Pfizer Inc., Octapharma AG, Bausch Health Companies Inc., Amneal Pharmaceuticals Inc., Fresenius Kabi AG, Perosphere Pharmaceuticals Inc., Ferring Pharmaceuticals Inc., Midas Pharma GmbH, Healthy Life Pharma Pvt. Ltd, Pharma Cure Laboratories, AMAG Pharmaceuticals, Inc., SGPharma Pvt. Ltd., Alps Pharmaceutical Ind. Co., Ltd., and Nischi Lifesciences
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • The global anticoagulant reversal drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global anticoagulant reversal drugs market

Detailed Segmentation:

  • Global Anticoagulant Reversal Drugs Market, By Drug Type:
    • Prothrombin Complex Concentrates
    • Phytonadione
    • Andexanet Alfa
    • Idarucizumab
    • Protamine
    • Others
  • Global Anticoagulant Reversal Drugs Market, By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Others
  • Global Anticoagulant Reversal Drugs Market, By Region:
    • North America
      • By Drug Type
      • Prothrombin Complex Concentrates
      • Phytonadione
      • Andexanet Alfa
      • Idarucizumab
      • Protamine
      • Others
      • By Distribution Channel
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
      • By Country
      • U.S.
      • Canada
    • Latin America
      • By Drug Type
      • Prothrombin Complex Concentrates
      • Phytonadione
      • Andexanet Alfa
      • Idarucizumab
      • Protamine
      • Others
      • By Distribution Channel
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
      • By Country
      • Brazil
      • Mexico
      • Argentina
      • Rest of Latin America
    • Europe
      • By Drug Type
      • Prothrombin Complex Concentrates
      • Phytonadione
      • Andexanet Alfa
      • Idarucizumab
      • Protamine
      • Others
      • By Distribution Channel
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
      • By Country
      • Germany
      • U.K.
      • France
      • Italy
      • Spain
      • Russia
      • Rest of Europe
    • Asia Pacific
      • By Drug Type
      • Prothrombin Complex Concentrates
      • Phytonadione
      • Andexanet Alfa
      • Idarucizumab
      • Protamine
      • Others
      • By Distribution Channel
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
      • By Country
      • China
      • India
      • Japan
      • Australia
      • South Korea
      • ASEAN
      • Rest of Asia Pacific
    • Middle East
      • By Drug Type
      • Prothrombin Complex Concentrates
      • Phytonadione
      • Andexanet Alfa
      • Idarucizumab
      • Protamine
      • Others
      • By Distribution Channel
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
      • By Country
      • GCC
      • Israel
      • Rest of Middle East
    • Africa
      • By Drug Type
      • Prothrombin Complex Concentrates
      • Phytonadione
      • Andexanet Alfa
      • Idarucizumab
      • Protamine
      • Others
      • By Distribution Channel
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
      • By Country/Region
      • South Africa
      • Central Africa
      • North Africa
  • Company Profiles
    • Alexion Pharmaceuticals, Inc.*
      • Company Overview
      • Material Portfolio
      • Financial Performance
      • Key Highlights
      • Market Strategies
    • Boehringer Ingelheim GmbH
    • CSL Behring Limited
    • Pfizer Inc.
    • Octapharma AG
    • Bausch Health Companies Inc.
    • Amneal Pharmaceuticals Inc.
    • Fresenius Kabi AG
    • Perosphere Pharmaceuticals Inc.
    • Ferring Pharmaceuticals Inc.
    • Midas Pharma GmbH
    • Healthy Life Pharma Pvt. Ltd
    • Pharma Cure Laboratories
    • AMAG Pharmaceuticals, Inc.
    • SGPharma Pvt. Ltd.
    • Alps Pharmaceutical Ind. Co., Ltd.
    • Nischi Lifesciences

"*" marked represents similar segmentation in other categories in the respective section.

Table of Contents

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Snippet, By Drug Type
    • Market Snippet, By Distribution Channel
    • Market Snippet, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Drivers
    • Restraints
    • Market Opportunities
  • Impact Analysis
  • Pipeline Analysis
  • PEST Analysis
  • Regulatory Scenario
  • Market Trends
  • Key Highlights
  • Reimbursement Scenario
  • Mergers & Acquisitions

4. Global Anticoagulant Reversal Drugs Market - Impact of Coronavirus (Covid-19) Pandemic

  • Economic Impact
  • Impact on Clinical Trials and Drug Development
  • Government Initiatives

5. Global Anticoagulant Reversal Drugs Market, By Drug Type, 2017 - 2028, (US$ Mn)

  • Introduction
    • Market Share Analysis, 2021 and 2028 (%)
    • Y-o-Y Growth Analysis, 2018 - 2028
    • Segment Trends
  • Prothrombin Complex Concentrates
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
  • Phytonadione
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
  • Andexanet Alfa
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
  • Idarucizumab
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
  • Protamine
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
  • Others
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)

6. Global Anticoagulant Reversal Drugs Market, By Distribution Channel, 2017 - 2028, (US$ Mn)

  • Introduction
    • Market Share Analysis, 2021 and 2028 (%)
    • Y-o-Y Growth Analysis, 2018 - 2028
    • Segment Trends
  • Hospital Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
  • Retail Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
  • Others
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)

7. Global Anticoagulant Reversal Drugs Market, By Region, 2017 - 2028, (US$ Mn)

  • Introduction
    • Market Share Analysis, By Region, 2021 and 2028 (%)
    • Y-o-Y Growth Analysis, For Regions, 2018-2028
  • North America
    • Market Size and Forecast, By Drug Type, 2017 - 2028, (US$ Mn)
    • Market Size and Forecast, By Distribution Channel, 2017 - 2028, (US$ Mn)
    • Market Size and Forecast, By Country, 2017 - 2028, (US$ Mn)
    • U.S.
    • Canada
  • Latin America
    • Market Size and Forecast, By Drug Type, 2017 - 2028, (US$ Mn)
    • Market Size and Forecast, By Distribution Channel, 2017 - 2028, (US$ Mn)
    • Market Size and Forecast, By Country, 2017 - 2028, (US$ Mn)
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
  • Europe
    • Market Size and Forecast, By Drug Type, 2017 - 2028, (US$ Mn)
    • Market Size and Forecast, By Distribution Channel, 2017 - 2028, (US$ Mn)
    • Market Size and Forecast, By Country, 2017 - 2028, (US$ Mn)
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Russia
    • Rest of Europe
  • Asia Pacific
    • Market Size and Forecast, By Drug Type, 2017 - 2028, (US$ Mn)
    • Market Size and Forecast, By Distribution Channel, 2017 - 2028, (US$ Mn)
    • Market Size and Forecast, By Country, 2017 - 2028, (US$ Mn)
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
  • Middle East
    • Market Size and Forecast, By Drug Type, 2017 - 2028, (US$ Mn)
    • Market Size and Forecast, By Distribution Channel, 2017 - 2028, (US$ Mn)
    • Market Size and Forecast, By Country, 2017 - 2028, (US$ Mn)
    • GCC
    • Israel
    • Rest of Middle East
  • Africa
    • Market Size and Forecast, By Drug Type, 2017 - 2028, (US$ Mn)
    • Market Size and Forecast, By Distribution Channel, 2017 - 2028, (US$ Mn)
    • Market Size and Forecast, By Region/Country, 2017 - 2028, (US$ Mn)
    • South Africa
    • Central Africa
    • North Africa

8. Competitive Landscape

  • Heat Map Analysis
  • Market Share Analysis
    • Alexion Pharmaceuticals, Inc.
    • Company Overview
    • Product Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Boehringer Ingelheim GmbH
    • Company Overview
    • Product Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • CSL Behring Limited
    • Company Overview
    • Product Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Pfizer Inc.
    • Company Overview
    • Product Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Octapharma AG
    • Company Overview
    • Product Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Bausch Health Companies Inc.
    • Company Overview
    • Product Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Amneal Pharmaceuticals Inc.
    • Company Overview
    • Product Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Fresenius Kabi AG
    • Company Overview
    • Product Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Perosphere Pharmaceuticals Inc.
    • Company Overview
    • Product Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Ferring Pharmaceuticals Inc.
    • Company Overview
    • Product Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Midas Pharma GmbH
    • Company Overview
    • Product Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Healthy Life Pharma Pvt. Ltd
    • Company Overview
    • Product Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Pharma Cure Laboratories
    • Company Overview
    • Product Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • AMAG Pharmaceuticals, Inc.
    • Company Overview
    • Product Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • SGPharma Pvt. Ltd.
    • Company Overview
    • Product Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Alps Pharmaceutical Ind. Co., Ltd.
    • Company Overview
    • Product Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Nischi Lifesciences
    • Company Overview
    • Product Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
  • Analyst Views

9. Section

  • References
  • Research Methodology
  • About us and Sales Contact